Akebia Therapeutics, Inc.
NASDAQ:AKBABiotechnology
+$0.01 today
- Market cap
- $113.54M
- Beta
- 0.25
- P/E (TTM)
- -13.3
- EPS (TTM)
- -$0.08
Volume 7.09M
Average 4.03M
AKBA Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Akebia Therapeutics, Inc.NASDAQ: AKBA
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables declines year over year
Q1 FY2026 accounts receivables of $15.7M (cash outflow) fell 43.7% year over year, ahead of the -94.6% change in trailing-twelve-month accounts receivables.
Context
- Accounts receivables amounted to 6.0% of revenue in FY2025, up 3.5 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -43.7% holds above the trailing-twelve-month pace of -94.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (14.14M) USD
- Year-over-year change
- -449.5%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (14.14M) | -449.5% |
| FY2024 | 2024-12-31 | 4.05M | +307.0% |
| FY2023 | 2023-12-31 | 994K | -91.5% |
| FY2022 | 2022-12-31 | 11.7M | +148.7% |
| FY2021 | 2021-12-31 | (24.03M) | — |
Accounts Receivables vs competitors
How AKBA compares with its peers on the latest reported figures
- AKBA's LTM Mar 2026 accounts receivables of $1.97M is the 5th largest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of -94.6% is the lowest of 5, against a peer median of -40.0%.
- Accounts receivables amounts to 0.8% of revenue for AKBA, versus a peer median of 2.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $22.02M | — | — | 19.0% | |
| LTM Mar 2026 | $8.4M | -40.2% | -25.8% | 2.8% | |
| LTM Mar 2026 | $2.98M | -39.9% | +20.9% | 2.4% | |
| LTM Mar 2026 | $2.67M | -59.5% | — | 4.8% | |
| LTM Mar 2026 | $1.97M | -94.6% | — | 0.8% | |
| LTM Mar 2026 | $36K | +167.9% | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding AKBA) | $0 | -40.0% | -2.4% | 2.6% | |
Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (282.02M) | (92.56M) | (51.93M) | (69.41M) | (5.35M) |
| Depreciation & Amortization | 36.13M | 37.7M | 41.85M | 37.5M | 1.27M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 22.74M | 17.85M | 9.32M | 7.78M | 11.28M |
| Change in Working Capital | (105.61M) | (1.44M) | (20.73M) | (39.68M) | 16.47M |
| Accounts Receivables | (24.03M) | 11.7M | 994K | 4.05M | (14.14M) |
| Inventory | (24.95M) | 19.79M | (2.54M) | (28.4M) | (23.13M) |
| Accounts Payables | (11.74M) | 1.5M | (5.24M) | (1.36M) | 3.08M |
| Other Working Capital | (44.9M) | (34.42M) | (13.94M) | (13.96M) | 50.66M |
| Other Non-Cash Items | 98.54M | (34.7M) | (1.9M) | 23.15M | 44.31M |
| Operating Cash Flow | (252.97M) | (73.15M) | (23.38M) | (40.66M) | 67.99M |
| Capital Expenditures | (59K) | (114K) | 0 | (33K) | (291K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 40M | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | (7.93M) |
| Investing Cash Flow | 39.94M | (114K) | 0 | (33K) | (7.93M) |
| Debt Repayment | 44.78M | (33M) | (32M) | 7.9M | 4.63M |
| Common Stock Issued | 88.95M | 7.53M | 6.79M | 42.65M | 68.36M |
| Common Stock Repurchased | 0 | 0 | 0 | (1.27M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 40.07M | 1K | 385K | (63K) |
| Financing Cash Flow | 133.73M | 14.6M | (25.21M) | 49.66M | 72.93M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (79.29M) | (58.67M) | (48.59M) | 8.97M | 132.99M |
| Free Cash Flow | (253.02M) | (73.27M) | (23.38M) | (40.69M) | 67.99M |
Akebia Therapeutics, Inc.
NASDAQ:AKBA
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.